Both discussed combinations for pathway interference (MEK+PI3K/mTOR and MEK+CDK4,6) are not tumor specific therapies and bear the risk of severe side effects, as most cell types and tissues signal through these pathways and will also be affected. This evidence concerns the gene MAP2K7 and neoplasm.